Research Topics
| C H ChesnutSummaryAffiliation: University of Washington Country: USA Publications
| Collaborators
|
Detail Information
Publications
Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosisClaus Christiansen
Center for Clinical and Basic Research, Ballerup, Denmark
BMC Musculoskelet Disord 11:130. 2010..We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis...- Salmon calcitonin: a review of current and future therapeutic indicationsC H Chesnut
Osteoporosis Research Group, University of Washington, Seattle, WA, USA
Osteoporos Int 19:479-91. 2008.... - Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST studyCharles H Chesnut
Osteoporosis Research Group, Department of Radiology UWMC ORG, University of Washington Medical Center, Seattle, Washington 98105 4631, USA
J Bone Miner Res 20:1548-61. 2005..MRI analyses of os calcis or microCT/histomorphometric analyses of bone biopsies did not reveal consistent differences in architecture between CT-NS and placebo... - Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONECharles H Chesnut
Osteoporosis Research Group, University of Washington, Seattle, WA, USA
Curr Med Res Opin 21:391-401. 2005..As osteoporosis medications must be effective across different populations, an additional objective of BONE was to investigate and report the effect of oral ibandronate in North American and European women, as described here... - Short-term calcium supplementation has no effect on biochemical markers of bone remodeling in early postmenopausal womenU Ulrich
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington, USA
Arch Gynecol Obstet 270:230-4. 2004..This study was designed to assess changes in biochemical markers of bone remodeling in early postmenopausal women receiving calcium supplementation... - Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapyL A Marshall
Section of Reproductive Endocrinology, Virginia Mason Medical Center, Seattle, WA, USA
Obstet Gynecol 87:350-4. 1996..To assess the utility of urinary cross-linked N-telopeptides in monitoring bone resorption and predicting bone loss during GnRH agonist administration... - The relationship between skeletal and oral bone mineral density: an overviewC H Chesnut
Department of Radiology and Medicine, Osteoporosis Research Group, University of Washington Medical Center, Seattle, Washington, USA
Ann Periodontol 6:193-6. 2001.... - Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fractureC H Chesnut
University of Washington Medical Center, Seattle 98105, USA
J Bone Miner Res 16:2163-72. 2001..New methods are needed to provide insight into the causes and effects of bone fragility. The definition of osteoporosis, meanwhile, must still be considered a work in progress... - Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronateCharles H Chesnut
Osteoporosis Research Group, Department of Radiology, University of Washington Medical Center, Seattle, Washington 98195, USA
Drugs 66:1351-9. 2006..This review summarises the efficacy and safety of once-monthly oral ibandronate and discusses the implications of such a treatment in primary care in the US... - Bone remodeling and bone mineral density during pregnancyU Ulrich
Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
Arch Gynecol Obstet 268:309-16. 2003.... - An interactive tutorial-based training technique for vertebral morphometryJ C Gardner
Department of Radiology, University of Washington, Seattle, WA 98195-7115, USA
Osteoporos Int 12:63-70. 2001..The interactive tutorial-based approach provides standardized training methods and assures consistency of instructional technique over time... - Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host diseasePaul A Carpenter
Fred Hutchinson CRC, Seattle, Washington, USA
Biol Blood Marrow Transplant 13:683-90. 2007..12 (-2.28 to +4.24) among the controls and +1.43 (-0.29 to +3.72) for the bisphosphonate group (P = .0002). The greatest improvement in BMD was observed in children who received therapy with bisphosphonates... - Vertebral fracture diagnosis in the multinational BONE study of oral ibandronate: quality management in radiologyGabriele Armbrecht
Center of Muscle and Bone Research, Charite Campus Benjamin Franklin, Berlin, Germany
J Clin Densitom 11:221-31. 2008..This meticulous methodology provided a highly effective means of identifying vertebral fractures and recruiting the trial population in which to assess the efficacy of ibandronate in postmenopausal osteoporosis... - Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonatesMone Zaidi
The Mount Sinai Bone Program, Mount Sinai School of Medicine, New York, NY 10029, USA
Ann N Y Acad Sci 1117:273-82. 2007..The ibandronate story should serve as an important future paradigm for bisphosphonate development... - Denosumab in postmenopausal women with low bone mineral densityMichael R McClung
Providence Portland Medical Center, Portland, Oreg, USA
N Engl J Med 354:821-31. 2006..The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action... - Review of treatment modalities for postmenopausal osteoporosisRonald C Hamdy
East Tennessee State University, Johnson City, TN 37614, USA
South Med J 98:1000-14; quiz 1015-7, 1048. 2005..Drugs on the horizon include strontium ranelate, which has been shown to reduce vertebral and nonvertebral fracture risk, and zoledronic acid, an injectable bisphosphonate that increased bone density with once-yearly administration... - History of calcitoninCharles H Chesnut
Lancet 360:801. 2002 - Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosisMichael R McClung
Oregon Osteoporosis Center, Portland, Oregon 97213, USA
J Bone Miner Res 19:11-8. 2004..1% and 1.8%, respectively; p < or = 0.0001 versus placebo) with 2.5 mg ibandronate after 24 months. Oral ibandronate is a promising option for the prevention of postmenopausal bone loss... - Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient dataJonathan D Adachi
McMaster University, Hamilton, Ontario, Canada
Aging Clin Exp Res 17:150-6. 2005..These trials included two large vertebral fracture studies that used time-to-event methods to evaluate the effects of treatment on fracture risk, thereby allowing both the occurrence and the timing of fractures to be considered...